| Field | Specification |
|---|---|
| Mfr No | |
| Assay Type | |
| Detection Range | |
| Product Type | |
| Sample Type(s) | serum, plasma |
| Sensitivity | |
| Target |
Assay Principle
The ELISA assay is based on the competitive principle. Each well of the supplied microtiter plate has been pre-coated with recombinant SARS-CoV-2 Spike RBD-hFc protein. When HRP conjugated recombinant human ACE2 protein is added simultaneously to wells along with diluted human serum/plasma samples, immobilized RBD will bind human ACE2 protein. The binding of RBD to human ACE2 protein is dose-dependently inhibited by the presence of anti-SARS-CoV-2 human neutralization antibodies in serum samples. Following the sample incubation step, unbound ACE2-HRP conjugate is washed away. A Positive Control is a known human antibody (IgG1 subtype) that is specific for SARS-CoV-2 spike protein with a binding epitope for RBD binding site. The positive control antibody is validated by an established pseudovirus infection of cultured human cells for proven neutralization function. Human IgG1 isotype control is used as a Negative Control sample. The absorbance of the unknown sample can then be compared to the Positive and Negative controls to determine the absence or presence of anti-SARS-CoV-2 human neutralization antibodies. In the competition assay, the greater the amount of anti-SARS CoV-2 human neutralization antibodies in the sample, the lower the color development and optical density reading.
SARS-CoV-2 Neutralization Antibody Detection ELISA Kit is a Competitive ELISA for the quantitative determination of SARS-CoV-2 Neutralization Antibody Detection. In this competitive ELISA, sample analyte competes with a labeled competitor for a limited number of antibody binding sites, so signal is inversely proportional to analyte concentration.
Kit Components
The kit provides a pre-coated microplate, target standard for standard-curve generation, detection reagents (detection antibody and enzyme conjugate), wash buffer, substrate, and stop solution. Refer to the product datasheet for the complete component list and quantities.
Performance Data
| Target | SARS-CoV-2 Neutralization Antibody Detection |
|---|---|
| Sample Type | serum, plasma |
| Assay Type | Competitive |
| Test Principle | Competitive ELISA |
| Sensitivity | 7.0 ng/mL |
| Detection Range | 10–500 ng/mL |
| Precision | Intra-assay CV 10.0%; Inter-assay CV 15.0% |
| Specificity | Specifically detecting human ant-SARS-CoV-2 neutralization antibodies. |
✓ Quality tested for reproducibility and lot-to-lot consistency
Safety & Handling
This kit is validated for serum, plasma. Other matrices may require additional in-lab validation.
This assay has a sensitivity of 7.0 ng/mL and a detection range of 10–500 ng/mL. Samples reading outside the range should be diluted or concentrated.
The kit provides a pre-coated microplate, target standard for standard-curve generation, detection reagents (detection antibody and enzyme conjugate), wash buffer, substrate, and stop solution. See the datasheet for the full component list and quantities.
A standard microplate reader capable of measuring absorbance at 450 nm is required for this competitive ELISA.
Customization & Add-ons: Need this ELISA kit tailored to your workflow? We can help with bulk or custom pack sizes, species or analyte variants, matched antibody pairs and standards, alternate plate formats (48- or 96-well, strip-well), and assay development or custom ELISA solutions for targets not in our catalog. Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services — our team will follow up with feasibility details and next steps.
